Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. NOVEL ADENOSINE A2A AGONISTS IN RENAL TISSUE PROTECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The development of new treatments for the effective reduction of renal injury associated with acute renal failure and kidney transplantation will have a great impact on health care delivery to patients with renal disease. Acute ischemic renal failure affects 5 percent of hospitalized patients and has a mortality rate approaching 50 percent. At present, dialysis ...

    SBIR Phase I 2002 Department of Health and Human Services
  2. A2A ADENOSINE AGONIST ADJUNCT FOR SYSTEMIC ANTHRAX

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This project develops A2A adenosine receptor (A2AAR) agonists as adjuncts to antibiotics for the treatment of anthrax septicemia. It responds to the urgent need for better treatment of highly lethal infections by this bioterrorism/biowarfare agent. Phase I has two aims, pharmaceutical development and documentation of efficacy in clinically relevant settings. Th ...

    STTR Phase I 2002 Department of Health and Human Services
  3. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase I 2002 Department of Health and Human Services
  4. A2A ADENOSINE AGONISTS AS NEUROPROTECTANTS

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The central goal of this research is to develop a new drug to prevent spinal cord reperfusion injury secondary to aortic clamping that occurs frequently during thoracic surgery. Irreversible spinal cord injury resulting in paraplegia or paraparesis is the single most devastating complication of surgery on the thoracic and thor ...

    SBIR Phase I 2002 Department of Health and Human Services
  5. ADVANCED DIABETES MANAGEMENT SYSTEM

    SBC: Adherence Technologies Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): For the 10 million people in the U.S. with Type 2 diabetes, it is essential to follow strict regimens that include diet, weight, exercise, eye care and foot care. The prescribed regimen promotes glycemic control, which is correlated with better health. Many have proposed interventions that are either time/labor intensive and costly (regular phone calls from nu ...

    SBIR Phase I 2002 Department of Health and Human Services
  6. ACCUNURSE SYSTEM

    SBC: Adherence Technologies Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): The AccuNurse System has been successfully developed in Phase I to provide an easy-to-use "mentor" and communications tool for CNAs and nurses in skilled nursing units. Wireless and advanced speech technologies are merged into a conversational system that provides: individualized resident information, paperless documentation at the point of care, and many other ...

    SBIR Phase I 2002 Department of Health and Human Services
  7. SMALL MOLECULE BLOCKERS OF B. ANTHRACIS TOXIN

    SBC: Innovative Biologics Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this SBIR proposal is the identification of small molecules capable of blocking the cytotoxic action of Bacillus anthracis lethal toxin by blocking the transmembrane pore formed by the protective antigen component of the toxin. Such molecules are envisioned for use as drugs for the treatment of anthrax. The strategy to identify such compoun ...

    SBIR Phase I 2002 Department of Health and Human Services
  8. SURFACE-SENSITIVE LASER ARRAY DETECTS BREATH ALCOHOL

    SBC: American Research Corporation of Virginia            Topic: N/A

    DESCRIPTION (provided by applicant): A need exists for accurate, self-calibrating instrumentation capable of monitoring in real time the concentration of blood alcohol as evidenced by the alcohol content of exhaled breath. At present instrumentation capable of diagnosing breath alcohol content requires selection of a specific sample time, is not readily amenable to continuous monitoring and doe ...

    SBIR Phase I 2002 Department of Health and Human Services
  9. NASALLY-DELIVERED MUCOSAL SUBUNIT VACCINE FOR PLAGUE

    SBC: BIODEFENSE TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We have developed a plant-based adjuvant/carrier:antigen fusion technology that offers significant advantages over conventional injectable vaccination regimes including: safety, mucosal efficacy, ease of delivery, rapid scalability, unlimited supply potential, and cost-savings. This technology has significant potential in contributing to biodefense strategies ...

    STTR Phase I 2002 Department of Health and Human Services
  10. ACTIVITIES OF DAILY LIVING ENHANCEMENT PERFORMANCE TOOL

    SBC: CARLOW INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of the ADEPT project is to enhance the independence, autonomy, safety, and performance of patients with dementia in conducting activities of daily living (ADL). The overall objective of ADEPT development is to enhance patient care in Special Care Units (SCUs) through the further development and testing of a computerized, self-directed, traini ...

    SBIR Phase I 2002 Department of Health and Human Services
US Flag An Official Website of the United States Government